Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6575029 | 0.84 | CA2 (0.38) | CA2MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL7090127 | 0.82 | GAA (0.39) | CA2MAPT | |
| SCHEMBL30760679 | 0.82 | MAPT (0.37) | CA2MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL30760678 | 0.82 | MAPT (0.37) | CA2MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL4370834 | 0.82 | CA2 (0.39) | CA2MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL5408623 | 0.82 | CA2 (0.39) | CA2MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL23518789 | 0.80 | CA2 (0.35) | CA2MAPTALDH1A1KDM4E | |
| SCHEMBL6662248 | 0.80 | CA2 (0.35) | CA2MAPT | |
| SCHEMBL4915430 | 0.80 | CA2 (0.35) | CA2MAPTALDH1A1KDM4E | |
| SCHEMBL15489117 | 0.80 | CA2 (0.35) | CA2MAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624158-B2 | Compound for use in the treatment of; sepsis, urogential, psychological, nervous system, respiratory, inflammatory, skin vascular and arthritic; wound healing agents | PFIZER INC | 2003-09-23 | — | — | US | disclosed |
| US-20020072597-A1 | Purine derivatives | PFIZER INC. | 2002-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072597-A1 | Purine derivatives | ADORA2A, ADORA1, ADORA3 | CA2 2655/4885MAPT 4124/4885KMT2A 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.